The latest price target for Medtronic (NYSE:MDT) was reported by Citigroup on March 4, 2025. The analyst firm set a price target for $107.00 expecting MDT to rise to within 12 months (a possible 14.32% upside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Medtronic (NYSE:MDT) was provided by Citigroup, and Medtronic upgraded their buy rating.

The last upgrade for Medtronic PLC happened on March 4, 2025 when Citigroup raised their price target to $107. Citigroup previously had a neutral for Medtronic PLC.

The last downgrade for Medtronic PLC happened on August 14, 2024 when Stifel changed their price target from $100 to $85 for Medtronic PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medtronic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medtronic was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.

While ratings are subjective and will change, the latest Medtronic (MDT) rating was a upgraded with a price target of $92.00 to $107.00. The current price Medtronic (MDT) is trading at is $93.60, which is within the analyst’s predicted range.